Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 286-302
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.286
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.286
Table 2 Univariate and multivariate analyses of overall survival in patients with gastric cancer
Prognostic variables | Univariate analysis | Multivariate analysis | ||||
Hazard ratio | 95% confidence interval | P value | Hazard ratio | 95% confidence interval | P value | |
Sex | 0.99 | 0.584–1.679 | 0.97 | - | - | - |
Age | 1.372 | 0.820–2.296 | 0.229 | - | - | - |
Tumor location | 0.925 | 0.545–1.569 | 0.772 | - | - | - |
Histological grade | 0.736 | 0.420–1.288 | 0.283 | - | - | - |
Tumor size | 2.417 | 1.399–4.176 | 0.004a | 0.87 | 0.504–1.504 | 0.619 |
T stage | 3.184 | 1.687–6.007 | 0.000a | 2.651 | 1.295–5.423 | 0.008a |
N stage | 2.034 | 1.196–3.457 | 0.009a | 1.414 | 0.709–2.818 | 0.325 |
TNM stage | 1.946 | 1.168–3.243 | 0.011a | 0.912 | 0.469–1.774 | 0.786 |
CIP2A expression | 2.319 | 1.288–3.927 | 0.003a | 1. 802 | 1.012–3.210 | 0.046a |
- Citation: Zhao YX, Ma LB, Yang Z, Wang F, Wang HY, Dang JY. Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin. World J Gastrointest Oncol 2023; 15(2): 286-302
- URL: https://www.wjgnet.com/1948-5204/full/v15/i2/286.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i2.286